We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Neurodegeneration – Products

The Avacta logo.
Product News

Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study

Avacta Group plc announces the opening of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.
The EpicentRx logo.
Product News

EpicentRx Receives Fast Track Designation From the U.S. FDA for Lead Asset

EpicentRx, Inc. has announced that the FDA has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.
Discovery of Blood-Based Biomarkers in Neurodegenerative Diseases content piece image
Whitepaper

Discovery of Blood-Based Biomarkers in Neurodegenerative Diseases

The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.
ioGABAergic Neurons – iPSC-Derived Inhibitory Neurons With >95% Purity content piece image
Product
Advertisement

ioGABAergic Neurons – iPSC-Derived Inhibitory Neurons With >95% Purity

Discover ioGABAergic Neurons from bit.bio and avoid unwanted excitatory neurons obscuring inhibitory signals in your experiments. Using a simple protocol, consistently go from cryopreserved cells to mature, functional, experiment-ready hiPSC-derived GABAergic neurons with >95% purity in 12 days.
Professor Helen Walden, Dr Mehmet Gundogdu and Dr Sheelagh Frame.
Product News

Ubiquigent Collaborates With University of Glasgow on Translational Structural Biology

Ubiquigent Limited has announced it is supporting a Master’s student at the University of Glasgow to undertake a research project on USP30, a deubiquitinase implicated in neurodegenerative, renal and cardiovascular diseases.
Dr Alastair Smith, Chief Executive Officer of Avacta Group.
Product News

Avacta Announces Successful Completion of Fourth Dose Escalation in Phase 1 Clinical Study

Avacta Group plc announces that AVA6000 continues to show a very favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial.
A closeup of many different medications
Product News

Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease

Pheno Therapeutics Limited has announced that it has entered into an exclusive worldwide license agreement with UCB.
Collection of cells floating in a blue background.
Product News

MaxCyte Signs Strategic Platform License With Curamys To Enable Cell and Gene Therapies for the Treatment of Rare Intractable Diseases

Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
Developing Next-Generation <i>In Vitro</i> Phenotypic Assays for Huntington’s Disease content piece image
App Note / Case Study

Developing Next-Generation In Vitro Phenotypic Assays for Huntington’s Disease

There is currently no effective cure or treatment to slow down or stop the progression of Huntington's disease (HD). One reason for this is the lack of accurate and easy-to-use HD models.
Neurotrophic Factors (NTFs) for Neural Cell Culture content piece image
Product
Advertisement

Neurotrophic Factors (NTFs) for Neural Cell Culture

Neurotrophic factors (NTFs) control nerve cell proliferation and differentiation. The ability of these factors to promote cell survival and regeneration following injury, especially after stroke and brain injury, is applied in nerve cell culture and differentiation research. They are the first factors tested in the Central Nervous System (CNS) as therapeutic biologics.
Advertisement